Skip to content

Efficacy and safety of Simiao pill in the treatment of hyperuricemia

Efficacy and safety of Simiao pill in the treatment of hyperuricemia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053727
Enrollment
Unknown
Registered
2021-11-28
Start date
2021-11-17
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Sponsors

Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. In accordance with the diagnostic criteria of hyperuricemia, or conform to the diagnostic criteria of people of good health status; 2. Aged 18 to 30 years, male and female; 3. The subjects of hyperuricemia conforms to the clinical syndrome diagnosis standard of damp heat syndrome in traditional Chinese medicine; 4. The subjects are informed and voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Living with a serious adverse lifestyle; 2. With any infection in recent four weeks; 3. Pregnant or lactating women, or people who are allergic to the test drug; 4. Subjects who are taking part in other drugs clinical trials; 5. Volunteers whom researchers believe not suitable for the clinical trail with other reasons; 6. Hereditary disease; 7. Use of antibiotics, probiotics, prebiotics, or synbiotics in two months before collection of the fecal sample.

Design outcomes

Primary

MeasureTime frame
uric acid production and excretion;uric acid; the score of damp heat syndrome;

Secondary

MeasureTime frame
liver function;renal function;blood glucose;blood lipid;

Countries

China

Contacts

Public ContactZhao Xiaoshan

Southern Medical University

zhaoxs0609@163.com+86 18620277055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026